Sook Kyung Do1,2, Ji Yun Jeong3, Shin Yup Lee4,5, Jin Eun Choi1,6, Mi Jeong Hong1,6, Hyo-Gyoung Kang1,6, Won Kee Lee7, Yangki Seok8,9, Eung Bae Lee8,9, Kyung Min Shin10, Seung Soo Yoo8,11, Jaehee Lee11, Seung Ick Cha11, Chang Ho Kim11, Michael L Neugent12, Justin Goodwin13,14, Jung-Whan Kim12, Jae Yong Park15,16,17,18,19. 1. Department of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. 2. BK21 Plus KNU Biomedical Convergence Program, Department of Biomedical Science, Kyungpook National University, Daegu, Republic of Korea. 3. Department of Pathology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. 4. Lung Cancer Center, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea. shinyup@knu.ac.kr. 5. Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. shinyup@knu.ac.kr. 6. Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. 7. Medical Research Collaboration Center in Kyungpook National University Hospital and School of Medicine, Kyungpook National University, Daegu, Republic of Korea. 8. Lung Cancer Center, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea. 9. Department of Thoracic Surgery, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. 10. Department of Radiology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. 11. Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. 12. Department of Biological Sciences, The University of Texas at Dallas, Richardson, TX, USA. 13. Yale School of Medicine, New Haven, CT, USA. 14. Yale Graduate School of Arts and Sciences, New Haven, CT, USA. 15. Department of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. jaeyong@knu.ac.kr. 16. BK21 Plus KNU Biomedical Convergence Program, Department of Biomedical Science, Kyungpook National University, Daegu, Republic of Korea. jaeyong@knu.ac.kr. 17. Lung Cancer Center, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea. jaeyong@knu.ac.kr. 18. Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. jaeyong@knu.ac.kr. 19. Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. jaeyong@knu.ac.kr.
Abstract
BACKGROUND: This study was conducted to investigate whether polymorphisms of glucose transporter 1 (GLUT1) gene are associated with the prognosis of patients with non-small cell lung cancer (NSCLC) after surgical resection. METHODS: Five single nucleotide polymorphisms (SNPs) in GLUT1 were investigated in a total of 354 patients with NSCLC who underwent curative surgery. The association of the SNPs with patients' survival was analyzed. RESULTS: Among the five SNPs investigated, two SNPs (GLUT1 rs3820589T > A and rs4658G > C) were significantly associated with OS in multivariate analyses. GLUT1 rs3820589T > A was associated with significantly better OS (adjusted hazard ratio [aHR] = 0.57, 95% confidence interval [CI] = 0.34-0.94, P = 0.03, under dominant model), and rs4658G > C was associated with significantly worse OS (aHR = 1.91, 95% CI = 1.09-3.33, P = 0.02, under recessive model). In the stratified analysis by tumor histology, the effect of these SNPs on OS was only significant in squamous cell carcinoma but not in adenocarcinoma. When the two SNPs were combined, OS decreased as the number of bad genotypes increased (Ptrend = 4 × 10-3). CONCLUSIONS: This study suggests that genetic variation in GLUT1 may be useful in predicting survival of patients with early stage NSCLC.
BACKGROUND: This study was conducted to investigate whether polymorphisms of glucose transporter 1 (GLUT1) gene are associated with the prognosis of patients with non-small cell lung cancer (NSCLC) after surgical resection. METHODS: Five single nucleotide polymorphisms (SNPs) in GLUT1 were investigated in a total of 354 patients with NSCLC who underwent curative surgery. The association of the SNPs with patients' survival was analyzed. RESULTS: Among the five SNPs investigated, two SNPs (GLUT1 rs3820589T > A and rs4658G > C) were significantly associated with OS in multivariate analyses. GLUT1 rs3820589T > A was associated with significantly better OS (adjusted hazard ratio [aHR] = 0.57, 95% confidence interval [CI] = 0.34-0.94, P = 0.03, under dominant model), and rs4658G > C was associated with significantly worse OS (aHR = 1.91, 95% CI = 1.09-3.33, P = 0.02, under recessive model). In the stratified analysis by tumor histology, the effect of these SNPs on OS was only significant in squamous cell carcinoma but not in adenocarcinoma. When the two SNPs were combined, OS decreased as the number of bad genotypes increased (Ptrend = 4 × 10-3). CONCLUSIONS: This study suggests that genetic variation in GLUT1 may be useful in predicting survival of patients with early stage NSCLC.
Authors: Kwang Man Park; Hong Jae Lee; Ki-Tae Koo; Heithem Ben Amara; Richard Leesungbok; Kwantae Noh; Sang Cheon Lee; Suk Won Lee Journal: Tissue Eng Regen Med Date: 2020-01-22 Impact factor: 4.169